Tweedy Browne Co LLC Invests $195,000 in Embecta Corp. $EMBC

Key Points

• Tweedy Browne Co LLC has invested $195,000 in Embecta Corp by acquiring 20,095 shares of the company's stock during the second quarter.
• Embecta reported $1.12 earnings per share for the last quarter, exceeding analysts' estimates, and set FY 2025 guidance at 2.900 to 2.950 EPS.
• The company declared a $0.15 quarterly dividend, reflecting an annualized payout of $0.60 and a dividend yield of 4.4%, with a payout ratio of 41.96%.

Tweedy Browne Co LLC acquired a new position in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,095 shares of the company's stock, valued at approximately $195,000.

Other hedge funds also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new stake in shares of Embecta during the 1st quarter worth $154,000. Principal Financial Group Inc. lifted its stake in Embecta by 3.4% in the first quarter. Principal Financial Group Inc. now owns 289,605 shares of the company's stock worth $3,692,000 after purchasing an additional 9,601 shares during the last quarter. Comerica Bank lifted its stake in Embecta by 65.7% in the first quarter. Comerica Bank now owns 50,641 shares of the company's stock worth $646,000 after purchasing an additional 20,079 shares during the last quarter. GAMMA Investing LLC lifted its stake in Embecta by 2,100.4% in the first quarter. GAMMA Investing LLC now owns 19,826 shares of the company's stock worth $253,000 after purchasing an additional 18,925 shares during the last quarter. Finally, Public Sector Pension Investment Board lifted its stake in Embecta by 28.2% in the first quarter. Public Sector Pension Investment Board now owns 184,319 shares of the company's stock worth $2,350,000 after purchasing an additional 40,564 shares during the last quarter. 93.83% of the stock is owned by institutional investors.

Embecta Trading Down 1.4%

EMBC stock opened at $13.69 on Friday. The firm's 50-day moving average price is $14.20 and its two-hundred day moving average price is $12.10. Embecta Corp. has a 12-month low of $9.20 and a 12-month high of $21.48. The stock has a market capitalization of $800.73 million, a price-to-earnings ratio of 9.57, a PEG ratio of 0.77 and a beta of 1.10.

Embecta (NASDAQ:EMBC - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.35. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The firm had revenue of $295.50 million for the quarter, compared to analysts' expectations of $278.15 million. During the same quarter in the previous year, the company earned $0.74 earnings per share. The company's revenue for the quarter was up 8.4% compared to the same quarter last year. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Equities analysts predict that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Friday, August 29th were given a $0.15 dividend. The ex-dividend date was Friday, August 29th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.4%. Embecta's payout ratio is presently 41.96%.

Wall Street Analysts Forecast Growth

EMBC has been the subject of several recent research reports. Zacks Research downgraded shares of Embecta from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 7th. BTIG Research reissued a "buy" rating and issued a $25.00 price target on shares of Embecta in a research note on Friday, September 5th. Mizuho lowered their price target on shares of Embecta from $13.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday, July 16th. Weiss Ratings reissued a "hold (c-)" rating on shares of Embecta in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Embecta from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Embecta presently has a consensus rating of "Hold" and an average target price of $19.00.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.